Development of patient individualization medication method of ampicillin/sulbactam and vancomycin when cardiovascular surgery
Not Applicable
- Conditions
- cardiovascular surgery condition
- Registration Number
- JPRN-UMIN000007356
- Lead Sponsor
- Kagoshima University hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
Neonate,infant,child,dialysis patient
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What pharmacokinetic and pharmacodynamic mechanisms underlie individualized ampicillin/sulbactam and vancomycin dosing in cardiovascular surgery?
How does personalized ampicillin/sulbactam-vancomycin therapy compare to standard-of-care antibiotics for preventing post-cardiac surgery infections?
Which biomarkers correlate with optimal vancomycin efficacy or ampicillin/sulbactam resistance in cardiovascular surgical patients?
What adverse event profiles are associated with ampicillin/sulbactam and vancomycin in cardiovascular surgery, and how are they mitigated?
Are there alternative antibiotic combinations to ampicillin/sulbactam and vancomycin for cardiovascular surgery with improved safety or efficacy?